These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 18473793

  • 1. STAT 3 as a target for cancer drug discovery.
    Costantino L, Barlocco D.
    Curr Med Chem; 2008; 15(9):834-43. PubMed ID: 18473793
    [Abstract] [Full Text] [Related]

  • 2. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
    Furtek SL, Backos DS, Matheson CJ, Reigan P.
    ACS Chem Biol; 2016 Feb 19; 11(2):308-18. PubMed ID: 26730496
    [Abstract] [Full Text] [Related]

  • 3. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
    Zhao W, Jaganathan S, Turkson J.
    J Biol Chem; 2010 Nov 12; 285(46):35855-65. PubMed ID: 20807764
    [Abstract] [Full Text] [Related]

  • 4. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
    Gelain A, Mori M, Meneghetti F, Villa S.
    Curr Med Chem; 2019 Nov 12; 26(27):5165-5206. PubMed ID: 30027840
    [Abstract] [Full Text] [Related]

  • 5. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.
    Debnath B, Xu S, Neamati N.
    J Med Chem; 2012 Aug 09; 55(15):6645-68. PubMed ID: 22650325
    [No Abstract] [Full Text] [Related]

  • 6. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W, Xiao H, Lin J, Li C.
    J Med Chem; 2013 Jun 13; 56(11):4402-12. PubMed ID: 23651330
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
    Cerulli RA, Shehaj L, Tosic I, Jiang K, Wang J, Frank DA, Kritzer JA.
    Bioorg Med Chem; 2020 Jun 15; 28(12):115542. PubMed ID: 32503696
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
    Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5605-9. PubMed ID: 21788134
    [Abstract] [Full Text] [Related]

  • 13. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.
    Schust J, Sperl B, Hollis A, Mayer TU, Berg T.
    Chem Biol; 2006 Nov 15; 13(11):1235-42. PubMed ID: 17114005
    [Abstract] [Full Text] [Related]

  • 14. STAT-3 inhibitors: state of the art and new horizons for cancer treatment.
    Lavecchia A, Di Giovanni C, Novellino E.
    Curr Med Chem; 2011 Nov 15; 18(16):2359-75. PubMed ID: 21568920
    [Abstract] [Full Text] [Related]

  • 15. Chemical probes that competitively and selectively inhibit Stat3 activation.
    Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ.
    PLoS One; 2009 Nov 15; 4(3):e4783. PubMed ID: 19274102
    [Abstract] [Full Text] [Related]

  • 16. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH, Li C.
    J Mol Recognit; 2011 Nov 15; 24(2):254-65. PubMed ID: 21360612
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
    Furtek SL, Matheson CJ, Backos DS, Reigan P.
    Oncotarget; 2016 Nov 22; 7(47):77998-78008. PubMed ID: 27793003
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
    Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui JR.
    Eur J Med Chem; 2018 Sep 05; 157():887-897. PubMed ID: 30145375
    [Abstract] [Full Text] [Related]

  • 20. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.
    Groner B, Weber A, Mack L.
    Bioengineered; 2012 Sep 05; 3(6):320-5. PubMed ID: 22825353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.